Replies to post #703034 on NorthWest Biotherapeutics Inc (NWBO)

[Nemesis18]

Come on, you know that the NICE won't consider this 'vaccine' for funding from the limited NHS budget.
It's not ever going to happen, I'm afraid, as the per patient cost of SOC is 100th. of this 'vaccine's' projected cost to the NHS.

So you can see that, on that basis alone, it is a non-starter, in terms of creating anywhere near a meaningful revenue from Britain's Healthcare System.